Streetbeat News

Stock Prices

CATX

Perspective Therapeutics' stock is trading higher following a Buy rating and $1.20 price target initiation by B. Riley Securities.

Portfolio Pulse from Benzinga Newsdesk

January 26, 2024 | 8:38 pm

NOK

T

VZ

Analysts provided mixed views on AT&T Inc (NYSE:T), with KeyBanc maintaining a Hold rating due to mixed 4Q results and challenges in Mobility and Business Wireline revenue. Oppenheimer and Scotiabank analysts maintained positive outlooks, citing AT&T's transition to a pure connectivity provider and improved cash flow estimates. Verizon Communications Inc (NYSE:VZ) was noted for accelerating subscriber growth and higher-quality asset base. Nokia Corp (NYSE:NOK) was mentioned in relation to AT&T's capital spend and depreciation. AT&T's stock showed a slight increase.

Portfolio Pulse from Anusuya Lahiri

January 26, 2024 | 8:33 pm

CHDN

DKNG

FOX

FOXA

MGM

The Detroit Lions are one game away from Super Bowl LVIII and face the San Francisco 49ers as a 7.5 point underdog. Sportsbooks like DraftKings, BetMGM, and TwinSpires, units of Churchill Downs, are seeing a high volume of bets on the Lions, which could result in losses for them if the Lions win. The public, especially in Michigan where online betting is legal, is heavily backing the Lions. The game will be aired on FOX.

Portfolio Pulse from Chris Katje

January 26, 2024 | 8:32 pm

GSK

GSK Inc. (NYSE:GSK) stock is currently trading at $39.37, experiencing a 1.36% increase. Over the past month, the stock has risen by 5.59%, and over the past year, by 11.42%. The company's P/E ratio is lower than the Pharmaceuticals industry average, which could indicate that the stock is undervalued or that shareholders have lower growth expectations.

Portfolio Pulse from Benzinga Insights

January 26, 2024 | 8:30 pm

SPY

Jeremy Siegel, a well-known market analyst, has expressed a positive outlook on the market, predicting an 8-10% gain in the S&P 500 index for the current year.

Portfolio Pulse from Benzinga Newsdesk

January 26, 2024 | 8:21 pm

USO

A Trafigura-operated oil tanker caught fire after a Houthi strike near Yemen, according to Bloomberg. The incident could potentially disrupt oil shipments in the region, raising concerns over supply security. The United States Oil Fund (USO), an ETF that tracks the price of oil, may be affected by this event due to potential impacts on oil prices.

Portfolio Pulse from Benzinga Newsdesk

January 26, 2024 | 8:20 pm

GBTC

Oliver Renick from Schwab Network suggests Bitcoin ETFs are being used by 'whales' as an exit strategy rather than an entry point for traditional investors. Market dynamics have shifted, with strong cash flow, profits, and dividends driving outperformance. Bitcoin, lacking these fundamentals, stands out as a risky asset. Despite the introduction of Spot ETFs, Bitcoin's integration into the financial system hasn't led to widespread adoption by traditional investors. The price of Bitcoin has declined despite substantial inflows into ETFs like Grayscale's Bitcoin Trust (GBTC), indicating a disconnect. Technical and market challenges make a bullish case for Bitcoin difficult.

Portfolio Pulse from Murtuza Merchant

January 26, 2024 | 8:16 pm

DINO

HF Sinclair Inc. (NYSE:DINO) has seen a slight increase in its stock price by 0.09% in the current market session to $53.77, but experienced a decrease over the past month and year by 1.15% and 1.77%, respectively. The company's P/E ratio of 4.67 is lower than the industry average of 10.44, which could suggest that the stock is undervalued or that investors expect lower future performance.

Portfolio Pulse from Benzinga Insights

January 26, 2024 | 8:15 pm

PINS

Evercore ISI Group analyst Mark Mahaney has maintained an Outperform rating on Pinterest (NYSE:PINS) and increased the price target from $45 to $50.

Portfolio Pulse from Benzinga Newsdesk

January 26, 2024 | 8:14 pm

MRK

Merck & Co Inc (NYSE:MRK) reported that Keytruda, its cancer drug, showed a significant improvement in disease-free survival for patients with advanced bladder cancer post-surgery in the Phase 3 AMBASSADOR/KEYNOTE-123 trial. The data, presented at the ASCO GU Symposium, indicated a 31% reduction in disease recurrence or death risk compared to observation. Median DFS was 29.0 months for Keytruda versus 14.0 months for observation. The overall survival endpoint has not yet reached statistical significance. Keytruda's safety profile remained consistent with no new safety signals. MRK shares rose 0.53% to $120.77.

Portfolio Pulse from Vandana Singh

January 26, 2024 | 8:14 pm